AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17043732
Drug: Radioiodine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioiodine therapy (Group II)
Trial: 14560493
Drug: Olanzapine (10‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (10‐20 mg)
Trial: 14560493
Drug: Perphenazine (8‐40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perphenazine (8‐40 mg)
Trial: 11099366
Drug: 6.9% CHO‐electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.9% CHO‐electrolyte solution (CE)
Trial: 29618599
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg/d (ATV10)
Trial: 29618599
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg/d (ATV80)
Trial: 17095263
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine with 1:100,000 epinephrine buccal infiltration during each of the 5 phases of the menstrual cycle for groups 1 and 2; randomly selected day for group 3.
Trial: 15866643
Drug: Alendronate (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (70 mg/week) with vitamin D and calcium
Trial: 12060505
Drug: Fluconazole, 150
RxNorm normalized name: Fluconazole, 150 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole, 150 mg capsules, single dose repeated weekly for 2 weeks
Trial: 12060505
Drug: Ketoconazole, 200
RxNorm normalized name: Ketoconazole, 200 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole, 200 mg tablets, single dose repeated weekly for 2 weeks
Trial: 8184812
Drug: lovastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lovastatin (40 mg/day)
Trial: 8184812
Drug: pravastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pravastatin (40 mg/day)
Trial: 2453699
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of antiarrhythmic agents (quinidine, etmozin, disopyramide, mexitil, and allapinine)
Trial: 25705952
Drug: Ablative fractional
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ablative fractional 10,600‐nm CO2 laser treatment (3 treatments at 8-week intervals)
Trial: 20630042
Drug: Iron sucrose
RxNorm normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron sucrose (600 mg IV)
Trial: 16603135
Drug: High-dose acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose acute tryptophan depletion
Trial: 16603135
Drug: Low-dose acute
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose acute tryptophan depletion
Trial: 12595913
Drug: Moclobemide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (300 to 600 mg, divided in 2 to 3 doses)
Trial: 12595913
Drug: Moclobemide (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (600 to 900 mg/d)
Trial: 1467155
Drug: Oral magnesium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral magnesium supplementation (magnesium pyrrolidone carboxylic acid) at a dose of 360 mg/day
Trial: 24166742
Drug: Flunarizine 10
RxNorm normalized name: flunarizine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine 10 mg daily along with betahistine 16 mg and paracetamol 1 gm during episodes
Trial: 24166742
Drug: Betahistine and
RxNorm normalized name: betahistine
DrugBank: Betahistine (DB06698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine and paracetamol during episodes
Trial: 19777177
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with serial [(18)F] FDG-PET
Trial: 16829617
Drug: MenBvac vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenBvac vaccine
Trial: 14530753
Drug: Standard sedation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard sedation regimen (intravenous propofol at 0-5 mg.kg-1.hr-1 and alfentanil 30 microg.kg-1.hr-1)
Trial: 10968495
Drug: Bronchodilators without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bronchodilators without inhaled corticosteroids
Trial: 9046643
Drug: Assertion training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assertion training therapy
Trial: 9046643
Drug: No assertion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No assertion training therapy (control)
Trial: 8325071
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (cisplatin 50 mg/m2 and vindesine 3 mg/m2 for 2 courses)
Trial: 29929385
Drug: Testosterone replacement
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone replacement therapy (1000 mg long-acting undecanoate testosterone via intramuscular injection every 3 months)
Trial: 15928719
Drug: Oral L-arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral L-arginine (3.0 t.i.d p.o. for 30 days)
Trial: 15928719
Drug: Oral L-arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral L-arginine
Trial: 10338173
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL 1.5% mepivacaine with proximal digital pressure
Trial: 10338173
Drug: 40 mL
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mL 1.5% mepivacaine without digital pressure
Trial: 1752075
Drug: Once weekly
RxNorm normalized name: Actonel 35 4-Week Once Weekly Dosepack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly subcutaneous administration of recombinant human erythropoietin (rHuEPO) at a starting dose of 100 U/kg body wt/week
Trial: 1752075
Drug: Twice weekly
RxNorm normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice weekly subcutaneous administration of recombinant human erythropoietin (rHuEPO) at a starting dose of 100 U/kg body wt/week
Trial: 28911144
Drug: Group 1
RxNorm normalized name: Chlamydophila psittaci biogroup 1 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 (G1) - empiric two-pill/week dose increase followed by subsequent pill-per-week dose adjustments
Trial: 28911144
Drug: Group 2
RxNorm normalized name: Chlamydophila psittaci biogroup 2 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 (G2) - ongoing adjustment based on current TSH level and LT4 dose
Trial: 19678751
Drug: Prescription dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription dose NAPSO (550 mg twice daily)
Trial: 19678751
Drug: OTC doses
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OTC doses of NAPSO (220 mg two or three times daily)
Trial: 19678751
Drug: EC‐ASA 81
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC‐ASA 81 mg once daily
Trial: 1415367
Drug: 2.6% amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.6% amino acid solution
Trial: 16173387
Drug: Carisolv treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carisolv treatment
Trial: 12190173
Drug: Misoprostol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (400 microg, two doses)
Trial: 6113351
Drug: Effective CNS
RxNorm normalized name: CN-105
DrugBank: CN-105 (DB18345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effective CNS treatment before symptoms arise
Trial: 6113351
Drug: Prophylactic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic therapy
Trial: 6113351
Drug: Systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy and better general management
Trial: 29203503
Drug: Stimulation programme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulation programme administered by parents between 37 weeks' gestation and 6 months' corrected age
Trial: 29203503
Drug: Stimulation programme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulation programme administered by parents
Trial: 21739119
Drug: Trabectedin (1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabectedin (1.3 mg/m²)
Trial: 9893656
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (MA) 320 mg/day (two 160 mg tablets/day)
Trial: 8017124
Drug: Dried preparation
RxNorm normalized name: peptone,dried
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dried preparation of bifidumbacterin administered for 4-6 days
Trial: 8017124
Drug: Dried preparation
RxNorm normalized name: peptone,dried
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dried preparation of bifidumbacterin
Trial: 2681838
Drug: Indomethacin suppository
RxNorm normalized name: indomethacin Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin suppository (50 to 100 mg)
Trial: 27906800
Drug: Lactobacillus reuteri
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus reuteri DSM 17938 10⁸ CFU daily
Trial: 24063578
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment including Lugol's iodine staining
Trial: 24063578
Drug: Standard surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard surgical treatment arm
Trial: 10518847
Drug: Budesonide inhalation
RxNorm normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide inhalation suspension (BIS) at total daily doses of 0.25 mg, 0.5 mg, 1.0 mg, and 2.0 mg
Trial: 1837606
Drug: Alternative group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative group (1/5 of the treatment group's exercise program per session)
Trial: 1837606
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (completed training at least once a week for 1 year)
Trial: 7019266
Drug: 0.1% stannous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% stannous fluoride (SnF2), rinsed twice daily for 5 days
Trial: 7019266
Drug: 0.2% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% chlorhexidine digluconate, rinsed twice daily for 5 days after SnF2
Trial: 15948743
Drug: BCG (81
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG (81 mg Connaught strain)
Trial: 15948743
Drug: Epirubicin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin (50 mg)
Trial: 11837383
Drug: Moexipril 15
RxNorm normalized name: moexipril 15 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moexipril 15 mg single oral dose in fasting state
Trial: 11837383
Drug: Moexipril 15
RxNorm normalized name: moexipril 15 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moexipril 15 mg single oral dose in postprandial state
Trial: 11837383
Drug: Moexipril 15
RxNorm normalized name: moexipril 15 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moexipril 15 mg single oral dose
Trial: 11837383
Drug: Moexipril 15
RxNorm normalized name: moexipril 15 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moexipril 15 mg once daily for 5 days
Trial: 10445897
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group with access to case management and community care benefits (up to $699 per month)
Trial: 8665543
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 5 mg selegeline
Trial: 8665543
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 10 mg selegeline
Trial: 1706014
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (enalapril 20 mg + sustained-release diltiazem 300 mg)
Trial: 30610862
Drug: FMTv (Fecal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FMTv (Fecal Microbiota Transplantation after 4-10 days of vancomycin 125 mg 4 times daily)
Trial: 30610862
Drug: fidaxomicin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fidaxomicin (200 mg twice daily for 10 days)
Trial: 30610862
Drug: vancomycin (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vancomycin (125 mg 4 times daily for 10 days)
Trial: 19819004
Drug: Modified killed-whole-cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified killed-whole-cell cholera vaccine
Trial: 8968432
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of hydrochlorothiazide, atenolol, captopril, diltiazem‐SR, clonidine, and prazosin
Trial: 1319735
Drug: L (80
RxNorm normalized name: ASFOTASE ALFA 100MG/ML INJ 0.8ML (80MG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L (80 mg/day lovastatin)
Trial: 1319735
Drug: L +
RxNorm normalized name: Citracal + D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L + GG (80 mg/day lovastatin + 20 g/day guar gum)
Trial: 1319735
Drug: L +
RxNorm normalized name: Citracal + D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L + C (80 mg/day lovastatin + 16 g/day cholestyramine)
Trial: 30951267
Drug: Treating early,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treating early, intensively and to target (specific treatment details not provided)
Trial: 30951267
Drug: Treatment type
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment type (not specified)
Trial: 28328346
Drug: Live, oral
RxNorm normalized name: typhoid vaccine, live, oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live, oral bovine rotavirus pentavalent vaccine (BRV-PV)
Trial: 23515453
Drug: Org 43553
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Org 43553 (25-900 mg)
Trial: 23515453
Drug: Org 43902
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Org 43902 (30-300 mg)
Trial: 20980485
Drug: Serum concentrations
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum concentrations of 25(OH)D ≥ 30 ng/mL
Trial: 8085125
Drug: 1% glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% glucose solution
Trial: 8085125
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no glucose solution)
Trial: 1067480
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy with 6 mercaptopurine (6 MP) and methotrexate (MTX)
Trial: 1067480
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy with 6 mercaptopurine (6 MP), methotrexate (MTX) and cyclophosphamide (Cyclo)
Trial: 1067480
Drug: CNS prophylaxis
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNS prophylaxis with cranial radiation (2500 rad) and intrathecal administration of methotrexate (MTX) and prednisolone
Trial: 1067480
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment including induction therapy with vincristine (VCR) and prednisone (Pred)
Trial: 1067480
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment including maintenance therapy
Trial: 28379861
Drug: Extended-Release Injectable
RxNorm normalized name: Exenatide for Extended-Release Injectable Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-Release Injectable Naltrexone (XR-NTX) 380 mg, 6 monthly doses
Trial: 24460005
Drug: Jump 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jump 10 group (10 jumps, twice daily for 16 weeks)
Trial: 24460005
Drug: Jump 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jump 20 group (20 jumps, twice daily for 16 weeks)
Trial: 23411791
Drug: Whole body
RxNorm normalized name: MaxiVision Whole Body Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole body vibration training combined with conventional physical therapy training
Trial: 23411791
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy training
Trial: 6142208
Drug: Artificial surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artificial surfactant therapy (30 mg dipalmitoylphosphatidylcholine and 3 mg high-density lipoprotein in a 5 ml suspension)
Trial: 6142208
Drug: Artificial surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artificial surfactant therapy
Trial: 24661511
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (amoxicillin 40 mg/(kg·d), Tid; clarithromycin 15 mg/(kg·d), Bid; omeprazole 0.7-0.8 mg/(kg·d), Qd)
Trial: 24661511
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy combined with Saccharomyces boulardii (250 mg, Bid)
Trial: 23171757
Drug: Inactivated PCV2
RxNorm normalized name: poliovirus vaccine inactivated, type 1 (Mahoney)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated PCV2 vaccine
Trial: 20601905
Drug: Probiotic and
RxNorm normalized name: Florastor Advanced Probiotic And Digestive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic and prebiotic fortified milk (1.9 x 10 colony-forming units of Bifidobacterium lactis HN019 and 2.4 g/day of prebiotic oligosaccharides)
Trial: 15702140
Drug: TYR-free amino
RxNorm normalized name: Tyr
DrugBank: Tyrosine (DB00135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TYR-free amino acid drink (74 g, lacking TYR and PHE)
Trial: 12093460
Drug: 19.6 g
RxNorm normalized name: ALUMINUM CHLOROHYDRATE 19.6 g in 100 g TOPICAL STICK [Dove]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 19.6 g of arginine/d for 14 days (n = 6)
Trial: 11225649
Drug: Niacin-bound chromium
RxNorm normalized name: chromium picolinate / niacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacin-bound chromium 600 microg daily for 2 months
Trial: 7586602
Drug: Calculated dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calculated dose group (131I dose based on thyroid gland type, accurate volume measurement, and 24-hour uptake determination)
Trial: 7586602
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose group (fixed doses of 185, 370, or 555 MBq based on gland size assessment by palpation)
Trial: 30004570
Drug: PFNA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PFNA treatment
Trial: 18035199
Drug: Erdosteine 225
RxNorm normalized name: erdosteine
DrugBank: Erdosteine (DB05057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erdosteine 225 mg BID and chest physiotherapy
Trial: 29553432
Drug: General anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anaesthesia (20% intravenous propofol for induction, atracurium for muscle relaxation, nitrous oxide and oxygen for maintenance)
Trial: 29553432
Drug: Spinal anaesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anaesthesia (0.5% hyperbaric solution bupivacaine with 20 μg fentanyl intrathecally)
Trial: 20175608
Drug: Person-centered therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Person-centered therapy
Trial: 16304166
Drug: Azithromycin (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (oral and intravenous doses)
Trial: 2802118
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion (3.93 mg/kg)
Trial: 4404939
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g ampicillin daily
Trial: 4404939
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g ampicillin daily
Trial: 4404939
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g ampicillin daily + 20 mg prednisolone daily
Trial: 4404939
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g ampicillin daily + 20 mg prednisolone daily
Trial: 27158908
Drug: Benznidazole 5
RxNorm normalized name: Benznidazole 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benznidazole 5 mg/Kg/day for 60 days (n = 47)
Trial: 27158908
Drug: Benznidazole 5
RxNorm normalized name: Benznidazole 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benznidazole 5 mg/Kg/day open-label (n = 16)
Trial: 24069472
Drug: Benznidazole treatment
RxNorm normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benznidazole treatment